Fig. 3.

Effects of XE-991 (0.5–20 μM) on retigabine (30 μM)-induced submaximal relaxation of U46619 (0.1 μM)-precontracted longitudinal muscle strips of the rat gastric fundus. Mean retigabine (30 μM)-induced relaxations observed in the absence (0 XE-991, controls) or presence of XE-991 (0.5–20 μM). Relaxations were measured as peak amplitudes. Peak amplitudes are expressed as percentages of a maximal amplitude parameter measured from the maximal U46619-induced contraction point reached before the addition of any test substance to the maximal papaverine (300 μM)-induced relaxation point reached at the end of each experiment. Each point represents the mean ± s.e.m. of responses observed in three strips. Significant differences between test and control responses: ***P < 0.001.